Yifeng Pharmacy (603939) — Working Capital to Net Assets Ratio
Yifeng Pharmacy (603939) has a Working Capital to Net Assets ratio of 38.4% as of September 2025. Working capital of CN¥4.48 Billion (current assets of CN¥15.09 Billion minus current liabilities of CN¥10.61 Billion) is measured against net assets of CN¥11.66 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Yifeng Pharmacy financial flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Yifeng Pharmacy Working Capital to Net Assets (2011–2024)
This chart shows how Yifeng Pharmacy's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 38.4%, reflecting working capital of CN¥4.48 Billion against net assets of CN¥11.66 Billion CNY. See Yifeng Pharmacy (603939) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Yifeng Pharmacy (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Yifeng Pharmacy from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 603939 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 28.6% | CN¥3.26 Billion | CN¥11.39 Billion | CN¥15.86 Billion | CN¥12.60 Billion | ▲ +20.4 pp |
| 2023 | 8.2% | CN¥859.44 Million | CN¥10.45 Billion | CN¥12.13 Billion | CN¥11.27 Billion | ▼ -1.8 pp |
| 2022 | 10.1% | CN¥918.95 Million | CN¥9.12 Billion | CN¥10.58 Billion | CN¥9.66 Billion | ▼ -4.8 pp |
| 2021 | 14.9% | CN¥1.17 Billion | CN¥7.86 Billion | CN¥7.92 Billion | CN¥6.75 Billion | ▼ -35.7 pp |
| 2020 | 50.6% | CN¥2.92 Billion | CN¥5.78 Billion | CN¥8.06 Billion | CN¥5.14 Billion | ▲ +23.8 pp |
| 2019 | 26.8% | CN¥1.26 Billion | CN¥4.71 Billion | CN¥4.99 Billion | CN¥3.73 Billion | ▼ -5.4 pp |
| 2018 | 32.2% | CN¥1.34 Billion | CN¥4.17 Billion | CN¥4.24 Billion | CN¥2.90 Billion | ▼ -24.4 pp |
| 2017 | 56.6% | CN¥1.80 Billion | CN¥3.18 Billion | CN¥3.36 Billion | CN¥1.56 Billion | ▼ -8.1 pp |
| 2016 | 64.7% | CN¥1.93 Billion | CN¥2.98 Billion | CN¥3.13 Billion | CN¥1.20 Billion | ▲ +13.4 pp |
| 2015 | 51.3% | CN¥728.11 Million | CN¥1.42 Billion | CN¥1.74 Billion | CN¥1.01 Billion | ▲ +10.6 pp |
| 2014 | 40.7% | CN¥242.22 Million | CN¥595.76 Million | CN¥893.29 Million | CN¥651.06 Million | ▲ +3.5 pp |
| 2013 | 37.1% | CN¥186.45 Million | CN¥502.20 Million | CN¥706.01 Million | CN¥519.57 Million | ▲ +7.8 pp |
| 2012 | 29.3% | CN¥124.67 Million | CN¥425.82 Million | CN¥539.13 Million | CN¥414.46 Million | ▼ -5.3 pp |
| 2011 | 34.5% | CN¥123.08 Million | CN¥356.28 Million | CN¥610.16 Million | CN¥487.07 Million | — |